Hepion pharmaceuticals, inc. HEPA.US Overview
HEPA AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
HEPA Current Performance
-
Hepion pharmaceuticals, inc.
-1.01%
Avg of Sector
-0.79%
S&P500
HEPA Key Information
HEPA Financial Forecast
Unit : USD
HEPA Earnings Table
HEPA Profile
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Price of HEPA
HEPA FAQ
When is HEPA's latest earnings report released?
The most recent financial report for Hepion pharmaceuticals, inc. (HEPA) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HEPA’s short-term business performance and financial health. For the latest updates on HEPA’s earnings releases, visit this page regularly.
How much cash does HEPA have?
At the end of the period, Hepion pharmaceuticals, inc. (HEPA) held Total Cash and Cash Equivalents of 4.59M, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is HEPA's EPS continuing to grow?
According to the past four quarterly reports, Hepion pharmaceuticals, inc. (HEPA)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of HEPA?
Hepion pharmaceuticals, inc. (HEPA)’s Free Cash Flow (FCF) for the period is -1.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 69.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of HEPA?
The latest valuation data shows Hepion pharmaceuticals, inc. (HEPA) has a Price-To-Earnings (PE) ratio of -0.21 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.